Compugen (NASDAQ:CGEN) Stock Price Passes Above 200 Day Moving Average - What's Next?

Key Points

• Compugen stock crossed above its 200‑day moving average ($1.59) on Friday, trading as high as $2.38 and last at $2.36 on volume of about 1.06 million shares (roughly an 11.8% intraday gain), giving the company a market cap near $188M.
• Analysts are mixed—one Buy and one Sell—resulting in a MarketBeat consensus of Hold with a $4.00 target; the company reported Q3 EPS of -$0.07 (beating estimates) and revenue of $1.89M (also beating), but remains unprofitable with negative margins and ROE.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.59 and traded as high as $2.38. Compugen shares last traded at $2.36, with a volume of 1,059,671 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compugen in a research report on Wednesday, October 8th. HC Wainwright started coverage on shares of Compugen in a research note on Wednesday, January 7th. They issued a "buy" rating and a $4.00 price target on the stock. Finally, Wall Street Zen raised shares of Compugen from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Compugen has a consensus rating of "Hold" and a consensus target price of $4.00.

Compugen Trading Up 11.8%

The company has a market capitalization of $188.29 million, a price-to-earnings ratio of -7.87 and a beta of 2.85. The stock's 50 day moving average price is $1.63 and its 200 day moving average price is $1.59.

Compugen (NASDAQ:CGEN - Get Free Report) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Compugen had a negative return on equity of 53.60% and a negative net margin of 400.10%.The business had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.47 million. On average, research analysts expect that Compugen Ltd. will post -0.03 earnings per share for the current year.

Hedge Funds Weigh In On Compugen

Several hedge funds and other institutional investors have recently made changes to their positions in CGEN. Jane Street Group LLC raised its position in Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after acquiring an additional 359,785 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of Compugen by 20.6% during the 2nd quarter. ARK Investment Management LLC now owns 1,072,776 shares of the biotechnology company's stock worth $1,785,000 after purchasing an additional 183,107 shares during the last quarter. R Squared Ltd bought a new stake in shares of Compugen in the 2nd quarter valued at about $71,000. Raymond James Financial Inc. raised its holdings in shares of Compugen by 51.0% in the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company's stock valued at $149,000 after purchasing an additional 34,215 shares during the period. Finally, Osaic Holdings Inc. lifted its stake in Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock valued at $78,000 after purchasing an additional 34,045 shares during the last quarter. 12.22% of the stock is owned by institutional investors.

Compugen Company Profile

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.